2020_STAR_Agenda_Axonal_CMT

…CMTA’s funding and operations focus is on translational research that will lead as directly as possible to therapeutic treatments for CMT. Axonal forms of CMT affect the “electrical wire” that…

CMTA_2019-2020_Audited_Financial_Statements

…and supports research into the cause, treatment and cure of CMT disorders. The Association also facilitates education and support for persons affected by CMT disorders. (2) SUMMARY OF SIGNIFICANT ACCOUNTING…

NeuropathicPainCMT_GCarter_etal

…BS. Neuropathic pain of peripheral origin: advances in pharmacologic treatment. Neurology 1995;45(Suppl9):17-25. 21. Victor M, Adams R. Diseases of peripheral nerve. In: Victor M, Adams R, editors. Principles of neurology….
…employees, directors, officers, and other stakeholders of the organization, on a confidential and anonymous basis.  The receipt, retention, and treatment of complaints received by the organization regarding accounting, internal…

CMTA Whistleblower Policy

…employees, directors, officers, and other stakeholders of the organization, on a confidential and anonymous basis.  The receipt, retention, and treatment of complaints received by the organization regarding accounting, internal…

2021 Audited Financials

…information regarding CMT disorders. The Association encourages, promotes and supports research into the cause, treatment and cure of CMT disorders. The Association also facilitates education and support for persons affected…

CMTA_2018_Audited_Financial_Statements

…treatment and cure of CMT disorders. The Association also facilitates education and support for persons affected by CMT disorders. (2) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Accounting The financial…

Sample Press Release

…for a treatment for CMT, putting together a group of top-flight researchers and experts and directly funding their work. CMTA launched the Strategy to Accelerate Research, or STAR, in 2008…

Walk4CMT_Local_Day_of_Sponsorship_Template

…research for the types of CMT that affect approximately 90% of all people with CMT. We are aggressively fighting to find a pharmaceutical treatment, and, ultimately, a cure for all…

CMTA PITCHBOOK 6_singles

…in the works, including testing axon-sparing strategies involving inhibition of SARM1. Work on biomarkers, which indicate if a particular treatment is effective, is underway in CMT subtypes 1A, 1X, 2A…